Cipla Qilu Keytruda Biosimilar US Deal
Analysis based on 12 articles · First reported Sep 03, 2026 · Last updated Sep 04, 2026
The partnership positions Cipla to enter the lucrative US biosimilar market for Keytruda, potentially capturing significant revenue as the originator faces patent expiry. It also signals growing collaboration between Indian and Chinese pharma firms, which may intensify competition and put downward pressure on oncology drug prices in the US.
Cipla Ltd, through its wholly owned US subsidiary Cipla — Invagen Pharmaceuticals Inc, has entered into a strategic partnership with China-based Qilu Pharmaceutical for the exclusive licensing and supply of QL2107, a biosimilar to the blockbuster cancer drug Keytruda (pembrolizumab), in the United States. Under the agreement, Qilu will handle development, regulatory registration, and supply, while Cipla will commercialize the product in the US. The deal aims to improve access to advanced cancer therapies and lower treatment costs. This marks Cipla's second licensing pact with a Chinese drugmaker in a week, following its earlier agreement with SK Biopharmaceuticals for a bisimilar antibody-drug conjugate. The partnership reflects Cipla's strategy to build a strong oncology-focused biosimilar portfolio. QL2107 is a biosimilar to pembrolizumab, which is marketed by Merck (MSD) as Keytruda and generated over $31 billion in 2025. As Keytruda approaches its patent cliff, several drugmakers, including Astec LifeSciences with Formycon AG and Abbott Laboratories with Alvogen, are developing biosimilar alternatives. Financial terms of the deal were not disclosed.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard